PA tablets: Investigational compounds combining aspirin and omeprazole for cardioprotection

Kevin P. Bliden, Michael Brener, Martin G. Gesheff, Christopher J. Franzese, Ali Tabrizchi, Udaya Tantry, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review

Abstract

For most patients with prior cardiovascular events, preventing future secondary cardiovascular events requires life-long persistence with antiplatelet therapy. PA tablets (P: proton pump inhibitors; A: aspirin) are investigational compounds that were developed to provide the cardioprotective benefits of aspirin with the upper gastrointestinal protection of a proton pump inhibitor (e.g., omeprazole). The tablets are film-coated, coordinated-release tablets for oral administration that contain 40 mg immediate-release omeprazole and either 81 or 325 mg delayed-release aspirin. The goals of the clinical development program were to demonstrate the following: improved gastrointestinal safety of PA relative to enteric-coated aspirin alone; bioequivalence and comparative bioavailability between the PA compounds and currently marketed enteric-coated aspirin; and long-term safety. Two clinical pharmacology studies were also conducted to study the potential for interaction between PA32540 and clopidogrel.

Original languageEnglish (US)
Pages (from-to)785-797
Number of pages13
JournalFuture Cardiology
Volume9
Issue number6
DOIs
StatePublished - Nov 1 2013

Keywords

  • PA32540
  • PA8140
  • aspirin
  • dual antiplatelet therapy
  • omeprazole
  • secondary cardiovascular prevention

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'PA tablets: Investigational compounds combining aspirin and omeprazole for cardioprotection'. Together they form a unique fingerprint.

Cite this